Tenet Healthcare (NYSE: THC) had its price target increased by UBS AG from $41.00 to $46.00 in a research report released on Tuesday morning. UBS AG currently has a neutral rating on the stock.

A number of other firms have also recently commented on THC. Analysts at Deutsche Bank reiterated a buy rating on shares of Tenet Healthcare in a research note to investors on Friday, March 8th. They now have a $46.00 price target on the stock. Separately, analysts at CRT Capital upgraded shares of Tenet Healthcare from a fair value rating to a buy rating in a research note to investors on Friday, March 8th. They now have a $51.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Tenet Healthcare from $20.00 to $38.00 in a research note to investors on Thursday, March 7th. They now have a sector perform rating on the stock.

Tenet Healthcare opened at 44.16 on Tuesday. Tenet Healthcare has a 1-year low of $17.24 and a 1-year high of $44.33. The stock’s 50-day moving average is currently $39.7. The company has a market cap of $4.605 billion and a price-to-earnings ratio of 34.07.

Tenet Healthcare Corporation, and its subsidiaries (Tenet) is an investor-owned health care services company whose subsidiaries and affiliates own and operate acute care hospitals, ambulatory surgery centers, diagnostic imaging centers and related health care facilities.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.